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Abstract
Background: The occurrence of cancer during pregnancy merges two complex, poorly understood
metabolic and hormonal conditions. This association can exacerbate the conditions of both the mother and
the foetus. The branched-chain amino acid leucine enhances cellular activity, particularly by increasing
protein synthesis. This study aimed to analyse the modulatory effect of a leucine-rich diet on direct and
indirect tumour-induced placental damage. This was accomplished by evaluating the expression of genes
involved in protein synthesis and degradation and assessing anti-oxidant enzyme activity in placental tissues
collected from pregnant, tumour-bearing rats.
Results: Pregnant rats were either implanted with Walker 256 tumour cells or injected with ascitic fluid
(to study the indirect effects of tumour growth) and then fed a leucine-rich diet. Animals in a control
group underwent the same procedures but were fed a normal diet. On the 20th day of pregnancy, tumour
growth was observed. Dams fed a normoprotein diet showed the greatest tumour growth. Injection with
ascitic fluid mimicked the effects of tumour growth. Decreased placental protein synthesis and increased
protein degradation were observed in both the tumour-bearing and the ascitic fluid-injected groups that
were fed a normoprotein diet. These effects resulted in low placental DNA and protein content and high
lipid peroxidation (measured by malondialdehyde content). Decreased placental protein synthesis-related
gene expression was observed in the tumour group concomitant with increased expression of genes
encoding protein degradation-associated proteins and proteolytic subunits.
Conclusions: Consumption of a leucine-rich diet counteracted the effects produced by tumour growth and
injection with ascitic fluid. The diet enhanced cell signalling, ameliorated deficiencies in DNA and protein
content, and balanced protein synthesis and degradation processes in the placenta. The improvements in
cell signalling included changes in the mTOR/eIF pathway. In conclusion, consumption of a leucine-rich diet
improved placental metabolism and cell signalling in tumour-bearing rats, and these changes reduced the
deleterious effects caused by tumour growth.
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Background
Cancer is the second leading cause of disease-mediated
death. The most common types of cancer in women are
breast and cervical cancers [1, 2]. Neoplasias are difficult
to control and treat because they are associated with
several biochemical and metabolic changes. These
changes increase overall metabolic consumption in
the host, especially in the skeletal muscle, and decrease
lean body mass. This culminates in reduced quality of life
and decreased survival in affected patients.
Moreover, the prevalence of cancer during pregnancy
is not rare, and the coexistence of these two complex
metabolic and hormonal conditions can negatively im-
pact the mother and foetus [3, 4]. To date, few studies
have reported on the influence of pregnancy on cancer
and vice versa [3, 4]. Recent publications have indicated
that pregnancy offers a protective effect against cancer,
but other reports suggest that pregnancy can accelerate
the growth and development of neoplasias. Furthermore,
there are difficulties associated with diagnosing early-
stage tumours in pregnant women [5, 6]. Zemlickis and
colleagues [7] found that patients diagnosed with breast
cancer during pregnancy exhibited more advanced tu-
mours and a higher incidence of metastasis compared to
non-pregnant controls. King and colleagues [8] found a
greater incidence of advanced stage tumours in patients
who were pregnant. Pregnant patients with cancer can
exhibit a more advanced evolution of the disease due to
delays in diagnosis and because the hormonal and
physiological changes that accompany pregnancy can re-
sult in a more aggressive disease response.
The endocrine changes associated with cancer evolu-
tion during pregnancy have not been well studied
because of the many physiological adaptations that con-
comitantly occur in the maternal organism. These adap-
tations are primarily driven by the maternal/foetal unit
known as the placenta [9, 10]. Thus, additional studies
examining how neoplastic progression is affected by the
complex alteration of hormonal homeostasis imposed by
pregnancy are needed. The aim of the current study was
to evaluate how tumour development affects cellular ac-
tivity in the placenta and how these changes interfere
with placental protein metabolism. Previous studies have
also shown that humoural factors produced by tumours
and/or host cells can indirectly interfere with placental
and foetal integrity. The consumption of a leucine-rich
diet can enhance cellular activity; as such, this study
also aimed to analyse the modulatory effect of nutri-
tional supplementation of leucine on tumour-induced
placental damage. This was accomplished by evaluat-
ing the expression of genes involved in protein syn-
thesis and degradation and by assessing anti-oxidant




Sixty adult female Wistar rats were obtained from the
Animal Care Center at the CEMIB (Multidisciplinary
Center for Biological Research of UNICAMP) and
housed in the experimental room located in the Labora-
tory of Nutrition and Cancer. The animals received food
and water ad libitum and were maintained under con-
trolled light and temperature conditions (12 h light-12 h
darkness, 22 + 2 °C, and 60 % relative humidity). To
obtain pregnant rats, inbred mating was performed
using 4 females per 1 male. Mating was allowed to occur
for 12 hours, and pregnancy was detected by assessing
vaginal smears for the existence of sperm. The pregnant
rats were subsequently distributed into 6 groups (mini-
mum of 10 animals per group). Three groups were fed a
control diet: a control group (C), Walker tumour-
bearing group (W), and ascitic fluid-injection group (A).
The remaining three groups were fed a leucine-rich diet:
a leucine-fed control group (L), tumour-bearing group
(LW), and ascitic fluid-inoculation group (LA). Each ani-
mal in the two tumour-bearing groups (W and LW) was
subcutaneously injected with approximately 1 × 106-
viable Walker 256 tumour cells on the second day of
pregnancy. Each animal in the ascitic fluid injection
groups (A and LA groups) was injected with ascitic fluid
from the 9th to the 20th day of pregnancy [11]. All of the
animals were weighed three times per week. At the end
of the experiment (20th day of pregnancy), the dams
were sacrificed, and samples of placenta were collected,
weighed and quickly frozen in liquid nitrogen. They
were subsequently stored at −80 °C for later biochemical
and molecular analysis. Fresh placental tissues were im-
mediately used for protein and degradation assays. At
the time of dam sacrifice, the foetuses were weighed and
counted, and the number of foetal resorptions was
recorded.
The experimental protocol used to conduct this re-
search was approved by the Ethics Committee on Animal
Experimentation of the Institute of Biology at the State
University of Campinas (UNICAMP), protocol number
2071–1. Additionally, the care and handling of the
tumour-bearing animals was in accordance with the rules
of the United Kingdom Coordinating Committee on
Cancer Research, an international organization [12].
Diets
The semipurified diets used in this study were equivalent
to diets produced by the American Institute of Nutrition
(AIN-93G) [13] and contained the same amounts of pro-
tein, calories and lipids. The diets were normoproteic,
isocaloric and normolipidic. The control diet (C) con-
tained 18 % protein and was composed of 20 % casein
(as a protein source); 39.7 % corn starch, 13.2 % dextrin,
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and 10 % sugar (as carbohydrate sources); 7 % soy oil (as
a fat source); 5 % cellulose micro fibre (as a fibre
source); 3.5 % salt mix; 1.0 % vitamin mix; 0.3 % cysteine
and 0.25 % choline. The leucine-rich diet (L) also con-
tained 18 % protein and was composed of the same
amounts of casein, fat, fibre, salt, vitamin mix, cysteine
and choline as the control diet, as well as 3 % leucine
and 38.7 % corn starch, 12.2 % dextrin, and 9 % sugar
(as carbohydrate sources). The control diet contained
1.6 % L-leucine. The leucine-rich diet contained
4.6 % L-leucine [1, 2].
Biochemical and molecular analyses
Placental synthesis and protein degradation
Fresh placental tissues were removed and individually
placed into tubes for perfusion with Krebs-Henseleit
buffer (KHB) (110 mM NaCl, 25 mM NaHCO3,
3.4 mM KCl, 1 mM CaCl2, 1 mM KH2PO4, 1 mM
MgSO4, 5.5 mM glucose, 0.01 % (w/v) bovine serum
albumin, pH 7.4). The placentas were pre-incubated
for 30 min at 37 °C with continuous shaking and gas-
sing (95 % O2 + 5 % CO2) [14]. Following this, fresh
KHB buffer solution supplemented with phenylalanine
(75 mmol L-phenylalanine and 50 mCi L-[2,6-3H]
phenylalanine/mL, Amersham) was added and incu-
bated for an additional 2 h. Next, the placentas were
removed from the medium, dried, weighed, homoge-
nised in 30 % TCA (1:3 w/v), and centrifuged at
10,000 x g for 15 min at 4 °C. The pellet was washed
twice with 10 % TCA to remove radioactivity from
the supernatant and then suspended in 1 M NaOH
and incubated at 40 °C for 30 min. Aliquots were
analysed for protein content [15], and radioactivity
was measured using a liquid scintillation β counter
(Beckman LS 6000 TA, Fullerton, CA). The rate of
placental protein synthesis was calculated as the
amount of radioactive phenylalanine incorporated into
the precipitated protein in 2 h and expressed as
nanomoles of [3H]-phenylalanine per microgram of
placental protein per hour [14].
Another sample of fresh placenta was used to ana-
lyse protein degradation, which was expressed as
nmol of tyrosine released per microgram of protein
per hour. The placenta sample was pre-incubated for
30 min at 37 °C with RPMI-1640 medium without
phenol. Following this, the sample was incubated
with KHB buffer supplemented with 130 μg/mL cy-
cloheximide (a protein synthesis inhibitor) for 2 h at
37 °C and then gassed with 5 % CO2 + 95 % O2.
Next, an aliquot of the incubation medium was
assessed for tyrosine content, which was measured
fluorometrically using 1-nitroso-2-naphthol and ni-
tric acid (20 %) according to a method published by
Waalkes & Udenfriend [16].
Analysis of placental DNA content and enzyme activity
Placental tissue was homogenised in homogenisation
buffer (0.1 M NaCl; 10 mM EDTA; 0.03 M Tris–HCl,
pH 8.0; 0.2 M sucrose and 0.01 % SDS) and incubated
for 1 h at 65 °C. Subsequently, 8 M potassium acetate
was added, followed by incubation and centrifugation
under refrigeration. DNA was extracted from the upper
phase using phenol:chloroform:isoamyl alcohol (25:24:1)
and then precipitated with 100 % ethanol overnight at
−80 °C. DNA content was quantified by measuring the
260/280 nm absorbance ratio using a spectrophotom-
eter. The coefficient of variation (CV) ranged from 6.5 %
to for the control, tumour and ascitic fluid samples.
Aliquots of placental homogenate supernatant were
analysed for alkaline phosphatase (AP) activity using
37 mM 4-nitrophenyl disodium phosphate (p-NPP;
Sigma). AP activity was expressed in nmol/min/mg
protein [17]. For this assay, the CV ranged from 10.3 %
to 20.8 % among all experimental groups. Glutathione
S-transferase (GST) activity was assessed in the pla-
cental samples based on the conjugation of 1-chloro-
2,4-dinitrobenzene (CDNB; Sigma) with glutathione.
The activity was expressed as nmol/μg protein/min
and calculated using an extinction coefficient of 9.6
as previously described [17] (the CV was ≤24.7 %).
Placental glutathione reductase was measured following
the method described in our previous work [17] (the CV
was ≤14.1 % among the groups). The lipid peroxidation
product malondialdehyde (MDA) was quantified by incu-
bating the samples with n-methyl-2-phenylindole (MPO;
Sigma) and then reading the absorbance at 590 nm. The
results are expressed as nmol/μg protein [18], and the CV
ranged up to 18.1 % for all samples.
Measuring the expression of placental protein
synthesis-associated and protein degradation-associated
genes by quantitative RT-PCR
Samples of placental tissue (10 mg) were lysed in 1 mL
TRI reagent solution (Sigma Aldrich, Co, Ltd.; Dorset,
UK), and total RNA was extracted as described by the
manufacturer. The RNA concentration was determined
based on the absorbance at 260 nm. cDNA was synthe-
sised from 3 μg of placental RNA in a volume of 20 μL
using MultiScribe™ Reverse Transcriptase and ran-
dom hexamer primers (High Capacity cDNA Reverse
Transcription Kits; Applied Biosystems, Foster City,
CA, USA). To amplify cDNA using real-time PCR,
reactions were performed in a total volume of 20 μL
containing 5 mM each primer, 4 μL cDNA (20x di-
luted), 4 μL milli-Q H2O and 10 μL Fast SYBR
Green 2X Master Mix (Applied Biosystems, Foster City,
CA). The placenta samples were denatured at 95 °C for
10 min, followed by 40 PCR cycles at 95 °C/60 °C. PCR
amplification was performed in triplicate. Quantitative
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PCR assays were performed using a StepOne Real Time
System (Applied Biosystems, Foster City, CA). The purity
of the amplified PCR products was verified based on melt-
ing curves. Target gene expression was analysed using
7500 Fast Real-Time PCR software, version 2.0.5 (Applied
Biosystems, Foster City, CA), and the values are expressed
relative to control levels (2-ΔΔCt). We analysed the expres-
sion levels of the protein degradation-associated and pro-
tein synthesis-associated genes as described in Table 1. To
confirm the integrity of the extracted RNA, transcription
of the housekeeping gene glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (NM_017008.4) was used as an in-
ternal control.
Western blotting to determine placental protein expression
Placenta samples were homogenised in protein extrac-
tion buffer (100 mM Tris Base, 10 mM Na4P2O7,
100 mM FNa, 1 mM Na3 VO4, 10 mM EDTA, 2 mM
PMSF, 0.1 mg/mL aprotinin, 1 % Triton X-100, pH 7.4)
followed by centrifugation at 10,000 × g for 15 min at 4 °C.
Placental proteins (40 μg) were resolved by 12 %
SDS-PAGE at 90 V for 1 h, followed by transfer onto
0.45-μm nitrocellulose membranes at 300 mA for 2 h.
The membranes were blocked with 5 % non-fat dry
milk in Tris-buffered saline (pH 7.5) for 1 h at room
temperature. The membranes were incubated overnight at
4 °C with primary antibodies against the 20S, 19S and 11S
proteasome subunits (#PW8165, #PW8195, Affinity, USA;
1:1500 dilution) as well as MuRF-1 (#SC-32920) and
MAFbx (#SC-33782; both from Santa Cruz Biotechnology,
Heidelberg, Germany; 1:200 dilution). Immunoreactivity
was detected by sequentially incubating the membranes
with specific secondary antibodies (1:10,000 dilution, Cell
Signaling Technology) for 1 h at room temperature and
visualised using a chemiluminescence detection system.
The blots were scanned using a gel image capture system
to quantify differences via densitometry (Alliance 2.7 sys-
tem, Alliance 1D capture software, and UVIBand 12.14
analysis software; UVITEC, Cambridge, UK). The levels of
all detected proteins were reported relative to the level of
34-kDa GAPDH.
Statistical analysis
The results are expressed as the mean ± S.E.M. All data
were assessed using the Kolmogorov-Smirnov normality
test, and the effects of diet, tumour presence, and ascitic
fluid on placental and foetal parameters were statistically
analysed by two-way ANOVA (Graph Pad Prism soft-
ware, version 5.0, San Diego, CA). Inter-group com-
parisons were made using the post hoc Bonferroni
multiple-comparison test. The results were considered
significant when P < 0.05 [19].
Results
Tumour growth deleteriously affects dam body weight
and foetal parameters
Tumour growth produced harmful effects on body
weight evolution in the W group: a significant variation
of 31 % was observed (P < 0.0045). However, injections
with ascitic fluid had no effect on body weight. Add-
itionally, regardless of tumour presence, the leucine-
treated group (WL) exhibited better body weight re-
covery compared to the C and L groups (Fig. 1a). In
this case, the interaction between tumour, ascitic fluid
and diet accounted for 20 % of the total variance and
was highly significant (P < 0.0234). As in our previous
Table 1 Detailed primers used to access the protein degradation and synthesis processes in placenta tissue
Protein degradation -associated
Gene Forward Reverse
PC5 NM_053590.1 GGACTTGATGAAGAAGGAAAGG GATGCCCTCTTTGGTCACTATG
PC2 NM_017278.1 CAGGAGTGTTTGGATTCCAG GTTAGCAGATGGACAGGTTTGG
Murf-1 NM_080903 TGAAGTGATCATGGACCGGC AATGCTCTTGATGAGCGGCTT
Atrogin NM_133521 ATGCCGTTCCTTGGTCAGG ATGGCGCTCCTTAGTACTCCC
Ubiquitin NM_031138.2 GAGGCTCATGCGGGATTTCAAG TCCTGATAAAGCTGTGCTGC
Calpain AB384822.1 GAACCGCATCCGGAATTACCTG GGTTGCAGCTGACCATGTTTGCA
Protein synthesis-associated genes
mTOR NM_001134499.2 CTCGTGAAGGACAACGGTCA TAGAGTTTTTCGTGGGCGCT
p70S6K1 NM_031985 GGCCCTGGGGATGCTGGAGA GGCTGACAGGCGTTCGTGGG
eIF4E NM_053974 ACCCCTACCACTAATCCCCC GCTTCAGTGCAGTCCACTCT
eIF4G NM_013507.3 ACCCACAATGGGACGTCATC CCGAGGTGGCATATCCTTCG
4EBP1 NM_053857.2 CGGCACGCTCTTCAGCACCA ACACCCAGTGTCTGCCGGGT
eIF5 XM_001479599.1 TGTCTGTCAACGTCAACCGCAG GAGGCATGCTTGACACACATC
eIF2α AK312442.1 GATCCATTGCTGAAATGGGG GATGACAAGTACAAGAGACCTGG
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experiments, a significant tumour effect leading to a
reduction in the number of foetuses was observed
(Fig. 1b, P = 0.0043). Additionally, tumour-bearing,
pregnant animals exhibited increased foetal resorption
and reduced foetal weight (Table 2; 38 % of total vari-
ance; P < 0.0047). Similarly, injections with ascitic
fluid resulted in decreased foetal number and weight
and increased foetal resorption (Fig. 1b and Table 2;
the ascitic effect accounted for 36 % of the total
variance, P < 0.0001). Tumour-bearing rats fed a
leucine-rich diet (WL) exhibited a non-significantly
decreased number of foetuses and increased foetus
resorption relative to the control group (C); however,
average foetal weight was significantly reduced com-
pared to the C and L groups. Consumption of a
leucine-rich diet minimised the effects caused by as-
citic fluid injection: foetal resorption rate were main-
tained. The interaction between ascitic fluid and diet
accounted for 20 % of the variation, which was sig-
nificant (P < 0.0321); however, the diet could not
Fig. 1 Body weight (a), foetal number (b), and foetal/placental weight ratio (c, eutrophic groups; d, groups fed a leucine-rich diet) in pregnant
rats of different experimental groups. Legend: Control (C), Leucine (L), Walker tumour-bearing rats (W), tumour-bearing rats fed a leucine-rich diet
(LW), ascitic fluid-injected rats (A) and ascitic fluid-injected rats fed a leucine-rich diet (LA). The results are expressed as the mean and standard
error. * P < 0.05 accounted by tumour effect, two-way ANOVA with Bonferroni testing, n = 10. Graphic C shows individual data corresponding to
foetal and placenta tissues obtained from each rat in each group; the C group curve has a slope of 2.61 slope for 74 analysed points. The W
group curve has a slope of 16.7 for 32 analysed points and is significant (P < 0.05) based on two-way ANOVA with Bonferroni testing (n = 10). The
A group curve has a slope of 0.92 for 38 analysed points. By linear regression analysis, it showed significant difference between slopes, F = 39.7,
P < 0.0001. Graphic D shows individual data corresponding to foetal and placenta tissues obtained from each rat in each group; the L group curve
has a slope of 0.70 for 87 analysed points. The LW group curve has a slope of 1.55 for 33 analysed points. The LA group curve has a slope of 2.07
for 36 analysed points. Linear regression analysis showed no difference among slopes (F = 0.19, P = 0.819)
Table 2 Foetal and placental parameters in Walker tumour-bearing rats and ascitic fluid-injected rats fed either a control or
leucine-rich diet






Foetal resorption per dam 0.900±0.314 3.300±0.538* 2.500±0.562* 0.889±0.309 1.600±0.499 1.700±0.473 P = 0.0321 P = 0.0043 n.s.
Foetal weight (g) 3.92 ± 0.07 2.73 ± 0.20* 2.61 ± 0.05* 3.65 ± 0.06 2.85 ± 0.08* 2.96 ± 0.09* n.s. P < 0.0001 n.s.
Placenta weight (g) 0.48 ± 0.01 0.53 ± 0.02 0.42 ± 0.02 0.52 ± 0.03 0.52 ± 0.01 0.50 ± 0.02 n.s. n.s. n.s.
Placental protein content (μg/mg) 7.38 ± 0.48 3.81 ± 0.29* 4.70 ± 0.34* 7.14 ± 0.28 6.87 ± 0.56 6.37 ± 0.67 P = 0.0043 P = 0.0002 n.s.
Placental DNA (μg/mg) 0.46 ± 0.02 0.38 ± 0.02* 0.38 ± 0.02* 0.46 ± 0.03 0.49 ± 0.02 0.43 ± 0.04 n.s. P = 0.0052 n.s.
Placental protein/DNA ratioa 16.8 ± 1.2 11.5 ± 0.9* 14.2 ± 1.5 17.3 ± 1.1 15.4 ± 1.5 17.3 ± 2.5 P = 0.0212 P = 0.0311 n.s.
Caption: Control (C), Leucine (L), Walker tumour-bearing rats (W), tumour-bearing rats subjected to a leucine-rich diet (LW), rats inoculated with ascitic fluid (A),
and rats inoculated with ascitic fluid and subjected to a leucine-rich (LA). The results are expressed as the mean and standard deviation. *P < 0.05 compared with
the control group. aPlacental protein/DNA ratio was used as an index of cell size. b Significant difference accounted by tumour, diet or interaction effect, analysed
by two-way ANOVA with Bonferroni testing, n.s. = non-significant
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correct for low foetal weight. The relationship be-
tween foetal weight and placental weight is indicative
of the efficiency of placental transport (Fig. 1c and
d). Foetal weight and placental weight were posi-
tively correlated in all groups except the tumour-
bearing group (W). This correlation indicates that
foetal and placental weights were not altered in par-
allel. As shown in the graph in Fig. 1c, variations in
placenta weight resulted in low foetal weight; the lin-
ear regression analysis showed the difference between
slopes was extremely significant (F = 39.7, P < 0.0001). In
contrast, in the LW group, there was a positive correlation
between placental and foetal weight. This relationship in-
dicated that placental weight influenced foetal weight in
this group (Fig. 1d; identical slopes, F = 0.19, P = 0.819).
Placental tissue damage caused by tumour growth
Placental weights were similar among the groups. How-
ever, in the tumour-bearing and ascitic fluid-injected
groups, placental protein content, DNA content, and
protein/DNA ratio, which represent cell number, all de-
creased (the effects were significant, P < 0.005; Table 2).
The same trends were not found in the leucine-rich diet
groups; the interaction effect was very significant, but
the diet had no effect overall (Table 2, P < 0.005). In
addition to the above tumour effects, placental protein
synthesis decreased in both the tumour-bearing (W) and
ascitic fluid-injected groups (A) (Fig. 2a). The tumour
and ascitic effects accounted for 15.0 % of the total vari-
ance and were significant (P = 0.0128). Consumption of
a leucine-rich diet significantly increased placental
phenylalanine incorporation in the L group (P = 0.0452)
but either had no effect or reduced phenylalanine incorp-
oration in the LW and LA groups (Fig. 2a). The tumour-
bearing group (W) exhibited increased protein degrad-
ation; the tumour effect was significant at P = 0.0378
(Fig. 2b). Consumption of a leucine-rich diet increased
placental tyrosine release in the L group. In the LW group,
placental tyrosine release was reduced compared with that
in the W group. The LA group exhibited a significant de-
crease, as the interaction effect between tumour/ascitic
fluid and diet was very significant (P = 0.0003, Fig. 2b).
Total protein levels in the placenta were very significantly
affected by the presence of tumours/injections with ascitic
fluid (15 % of total variance, P = 0.0018). This result indi-
cates reduced balance of total protein net in the tumour-
bearing and ascitic fluid-injected groups (Fig. 2c).
Overall cellular activity can be correlated with AP ac-
tivity [17, 20]. Tumour growth decreased placental en-
zyme activity only in the W group (Fig. 3a, P = 0.003).
Placental glutathione-S-transferase (GST) activity was
only reduced in W group tumour-bearing dams (account-
ing for 28 % of total variance, P = 0.0019). Consumption
of a leucine-rich diet significantly increased placental GST
activity in the LW and LA groups versus the L group
(Fig. 3b; interaction effect accounted for 16 % of variation,
P = 0.019). The reduced glutathione levels were constant
among the groups (Fig. 3c). Oxidative stress causes tissue
Fig. 2 Placental protein synthesis (a), protein degradation (b) and
protein balance (c) in pregnant rats from different experimental
groups. Legend: Control (C), Leucine (L), Walker tumour-bearing rats
(W), tumour-bearing rats fed a leucine-rich diet (WL), ascitic fluid-
injected rats (A) and ascitic fluid-injected rats fed a leucine-rich diet
(LA). The results are expressed as the mean and standard error. For
further details, see the Materials and Methods section. * P < 0.05
accounted by tumour effect, two-way ANOVA with Bonferroni testing,
n = 10. # P < 0.05 accounted by interaction between tumour/ascitic
with diet effect, two-way ANOVA with Bonferroni testing, n = 10
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damage, including lipid peroxidation and MDA release
[18]. Oxidative damage has been associated with tumour
growth. Placental tissue from the W group exhibited in-
creased MDA content. In this case, the tumour effect
accounted for 27 % of total variance and was extremely
significant (Fig. 3d, P = 0.0005). Additionally, the inter-
action between tumour/ascitic fluid and diet produced an
extremely significant effect (Fig. 3d, P = 0.0004). The
MDA/GST ratio is an indicator of damage induced by
poor cellular responses to external effects. The W group
exhibited a significantly higher MDA/GST ratio relative to
the other groups; the tumour effects in this group
accounted for the significant difference (P = 0.0065). Such
differences were not observed in the leucine-treated
tumour-bearing or ascitic fluid-injected groups, in this
case the interaction between tumour/ascitic fluid and diet
had a significant effect (Fig. 3e, P = 0.0368).
Tumour growth was associated with decreases in
mTOR and p70S6K1 gene expression, as well as re-
duced expression of eIF4E, eIF5 and eIF2a, three factors
involved in protein synthesis (Fig. 4a, b, c, f and g; the
tumour effect was highly significant at P < 0.05). Ascitic
fluid injection (A group) mimicked the indirect effects
of tumour growth, including reductions in the expres-
sion of eIF4E and 4EBP1 (Fig. 4c and e; the ascitic
fluid accounted for significant effects at P = 0.0504
and P = 0.0144, respectively). The leucine-supplemented
groups (LW and LA) exhibited similar profiles that
accounted for tumour/ascitic effects (10 % of the total
variance; P = 0.0144) (Fig. 4c, d, f and g).
Fig. 3 Activities of alkaline phosphatase (a), glutathione S-transferase (b), and reduced glutathione (c) in the placenta. Placental MDA
content (d) and MDA/GST ratios (e) in pregnant rats from different experimental groups. Legend: Control (C), Leucine (L), Walker
tumour-bearing rats (W), tumour-bearing rats fed a leucine-rich diet (WL), ascitic fluid-injected rats (A) and ascitic fluid-injected rats fed a
leucine-rich diet (LA). The results are expressed as the mean and standard error. * P < 0.05 accounted by tumour effect, two-way ANOVA
with Bonferroni testing, n = 10. # P < 0.05 accounted by interaction between tumour/ascitic with diet effect, two-way ANOVA with
Bonferroni testing, n = 10
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Protein degradation also increases during tumour
growth. Several key proteins were highly expressed in the
placental tissues of the animals in the W group. These in-
cluded MuRF-1, ubiquitin, ubiquitin-proteasome pathway
enzymes, and calpain, which is related to the calcium-
dependent proteolysis pathway. Tumour growth was
responsible for highly significant effects (Fig. 5c, e
and f; P = 0.027, P = 0.0147 and P = 0.0216). Similarly
to the tumour/ascitic effect, we also observed in-
creased expression of the MuRF-1 and ubiquitin
genes in the LW group (Fig. 5c and e) and increased
calpain gene expression increased in the LA group.
Expression of the 20S and MuRF-1 proteins also in-
creased, especially in the tumour-bearing groups (W
and LW groups; Fig. 6b, c, d and f; tumour growth
accounted for a significant effect at P = 0.0266). We
also observed increased 11S protein expression in the
L and LW groups, which were fed a leucine-rich diet;
the effect of the diet was significant (Fig. 6e; P = 0.0509).
No differences were observed among the groups with re-
spect to 19S and eIF2a (Fig. 6a and g).
Discussion
Tumour development, especially development of Walker
256 tumours, which serve as an experimental model of
cachexia [21, 22], promotes the breakdown of structural
tissue, including skeletal muscle mass [23], and increases
the production of protein waste in the host. Tumour
growth also affects other tissues and metabolic processes
[24, 25]. In our previous experimental studies [20, 26–28]
and in the present study, we found that tumour growth
causes severe damage during the course of pregnancy.
Fig. 4 Protein-synthesis gene expression in placental tissues of pregnant, Walker tumour-bearing rats and ascitic fluid-injected rats fed either a
control or leucine-rich diet. Mammalian target of rapamycin (mTOR) (a), p70-S6 kinase (p70S6K1) (b), eukaryotic initiation factors eIF4E (c) and
eIF4G (d), eukaryotic translation initiation factor 4 binding protein 1 (4EBP1) (e), eIF5 (f) and eIF2a (g) transcript levels in placental tissue quantified
by real-time PCR. Gene expression corrected by GAPDH as internal control. For additional details, see the Materials and Methods section. The
results are expressed as the mean and standard error. Legend: Control (C), Leucine (L), Walker tumour-bearing rats (W), tumour-bearing rats fed a
leucine-rich diet (WL), ascitic fluid-injected rats (A) and ascitic fluid-injected rats fed a leucine-rich diet (LA). * P < 0.05 accounted by tumour effect,
two-way ANOVA with Bonferroni testing, n = 10
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This damage is particularly harmful to placental tissue
and results in significant foetal weight loss and increased
foetal resorption [17, 20, 28]. Our previous results indi-
cated that supplementation with a leucine-rich diet could
prevent some of the effects induced by tumour evolution.
Consumption of a leucine-rich diet also minimised the in-
direct effects produced by injections with ascitic fluid. An-
imals consuming this diet exhibited improvements in
placental tissue health, leading to increased foetal num-
bers and enhanced expression of genes involved in placen-
tal cell signalling.
Foetal growth is primarily determined by nutrient
availability, which is related to the capacity of the
placenta to transport nutrients [29, 30]. Foetal macronu-
trient requirements for oxidative metabolism and growth
are met by placental transport, a process that is greatly
influenced by the maternal bloodstream and by placental
metabolism. The foetal nutrient supply is also consider-
ably affected by the conversion of glucose to lactate (or
fructose in some species) in the placenta and by the ex-
tensive transamination of amino acids. Placental capacity
for nutrient transport increases with foetal demand. As
such, maternal-foetal transport kinetics are tightly asso-
ciated with the expression and distribution of specific
transporters among placental cell types and with placen-
tal antioxidant response capacity against damage [17] or
Fig. 5 Protein-degradation gene expression in placental tissues of pregnant, Walker tumour-bearing rats and ascitic fluid-injected rats fed either a
control or leucine-rich diet. Ubiquitin-proteasome pathway members, including the 20S subunit, represented by the PC2 (a) and PC5 (b) genes;
muscle-ring finger protein 1 (MuRF-1) (c); ubiquitin ligase atrogin-1/MAFbx (d); ubiquitin (e); and a member of the calcium-dependent proteolytic
pathway, calpain (f), were quantified in placental tissue using real-time PCR. Gene expression corrected by GAPDH as internal control. For
additional details, see the Materials and Methods section. The results are expressed as the mean and standard error. Legend: Control (C),
Leucine (L), Walker tumour-bearing rats (W), tumour-bearing rats fed a leucine-rich diet (WL), ascitic fluid-injected rats (A) and ascitic
fluid-injected rats fed a leucine-rich diet (LA). * P < 0.05 accounted by tumour effect, two-way ANOVA with Bonferroni testing, n = 10
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reduced nutritional supply [29]. Abnormal placental
functioning affects foetal growth, especially during late
gestation [29–34]. Here, in pregnant, tumour-bearing
rats, the consequences of tumour evolution were dem-
onstrated. These included decreased body weight and
deleterious effects on foetal growth. These changes sug-
gest that the nutritional supply to the placenta and
foetus was diverted to benefit tumour growth. Indirect
tumour effects were assessed using an ascitic fluid injec-
tion model. This enabled the exclusion of nutritional fac-
tors from the observed placental and foetal damage and
reinforced that substances produced by tumour and/or
host cells can jeopardise the placenta and foetal
development.
Several reports have suggested that placental oxidative
stress is involved in the etiopathogenesis of pregnancy-
related diseases, such as preeclampsia, as well as in
foetal growth restriction [17, 29, 35–37]. Reduced
perfusion as a result of abnormal placentation leads
to ischemic injury and to increased oxidative stress in
preeclampsia [35, 36]. The activity of GST, an import-
ant detoxification enzyme related to reactive oxygen
species processing, can greatly contribute to both
foetal and placental antioxidative responses. Consist-
ent with this fact, the activity of this enzyme in-
creased in the groups inoculated with ascites fluid
and in the groups supplemented with a leucine-rich
diet (L, WL and LA). This result suggests that
placental tissue and foetal development were im-
proved. In a previous study, MDA and xanthine oxi-
dase (XO) levels were higher in maternal plasma,
umbilical cord plasma, and placental tissues of
20S - Band 3























Fig. 6 Key proteins involved in proteolysis in the placental tissues of pregnant, Walker tumour-bearing rats and ascitic fluid-injected rats fed either
a control or leucine-rich diet. Expression levels of ubiquitin-proteasome pathway members, including the 19S (a), 20S (b, c, and d) and 11S
subunits; (e), muscle-ring finger protein 1 (MuRF-1) (f); and the eukaryotic initiation factor eIF2a (g) in placenta tissue was quantified by western
blotting. For additional details, see the Materials and Methods section. The results are expressed as the mean and standard error. The images
represent one of 6 animals per group. Legend: Control (C), Leucine (L), Walker tumour-bearing rats (W), tumour-bearing rats fed a leucine-rich diet
(WL), ascitic fluid-injected rats (A) and ascitic fluid-injected rats fed a leucine-rich diet (LA). * P < 0.05 accounted by tumour effect, two-way
ANOVA with Bonferroni testing, n = 10. ϕ P < 0.05 accounted by diet effect, two-way ANOVA with Bonferroni testing, n = 10
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patients with intrauterine growth restriction (IUGR)
than in a control group [17, 35, 36]. Conversely, pa-
tients with IUGR exhibited lower antioxidant levels in
maternal plasma, umbilical cord plasma, and placental
tissues [36]. This reduction suggests that oxidative
stress increases in patients with IUGR [35, 38]. As
cancer also increases oxidative stress in host tissues
[17, 23], in the current study, we inferred that oxida-
tive stress-related damage in placental tissue resulted
from tumour growth effects. The observed increases
in foetal resorption and reductions in foetal weight
likely resulted from decreased placental antioxidative
responses. In the W group, increased lipid peroxida-
tion was also observed. Additionally, AP activity,
which is generally related to cellular activity and cel-
lular transport, was significantly reduced in the W
group. This reduction suggests that tumour growth
has deleterious effects on pregnancy. Conversely, pla-
cental dysfunction associated with increased lipid per-
oxidation (MDA) was significantly reduced in the
groups fed a leucine-rich diet (L, LW and LA). This
reduction was likely associated with the observed
positive responses and improvements in foetal and
placenta parameters in these groups [17, 20, 28].
Placental function is regulated by numerous factors of
foetal, maternal, and placental origin [34, 39–43]. These
factors may impact the placenta itself in an autocrine/
paracrine manner by integrating numerous and some-
times divergent intracellular regulatory signalling path-
ways [34, 41–43]. Moreover, changes in placental
nutrient transport capacity or supply and/or placental
cell activities may not be the primary factors responsible
for altered foetal growth, as we verified here in the W
group. Other factors could be involved in this harmful
process, as evidenced by the similar alterations observed
in the A group and the W group. Thus, the most im-
portant factor influenced by tumour evolution may be
the regulation of placental transport function by mater-
nal and foetal signalling molecules and placental cell sig-
nalling. It is important to note that the placenta
produces many cytokines and hormones that can act in
a paracrine or autocrine manner. These compounds can
be affected by humoural factors in ascitic fluid and likely
jeopardise placental activity, inducing foetal damage.
However, in the A group, several tumour effects were ei-
ther minimised or abolished, suggesting that placental
cell activity can be specifically regulated and that regula-
tory factors may have opposing effects on different pla-
cental process, such as placental transport and nutrient
provision to the foetus. Thus, the integration of multiple
stimuli is critical for adjusting placental function to ac-
commodate maternal and foetal welfare.
Placental trophoblast cells must integrate numerous
and possibly divergent maternal and foetal stimuli and
modify cellular functioning according to the host-
environment interaction, as we have previously reported
[17, 28]. Previous studies have demonstrated that pla-
cental signalling requires the integration of multiple
pathways, including the regulation of nutrient transport
and the regulation of the mTOR signalling pathway,
which is the main pathway regulating placental amino
acid transport [39–43]. Additionally, alterations in the
activity and/or expression of placental mTOR and
PPARγ have been observed in human pregnancies com-
plicated by altered foetal growth [31, 42]. It is likely that
the reduced foetal growth and increased foetal resorp-
tion observed in tumour-bearing rats had multifactorial
causes and were potentially associated with decreases in
the activities of cell signalling proteins. The above
changes are likely affected by placental protein synthesis
and degradation, two processes that can be differentially
affected by tumour factors (such as proteolysis-inducing
factor (PIF) or Walker factor (WF)) to cause foetal im-
pairment in different manners [31, 34]. The mTOR/eIF2
signalling pathway controls protein synthesis in response
to nutrient availability. Moreover, mTOR is a positive
regulator of placental nutrient transport and is involved
in the regulation of foetal growth. These functions are
consistent with the results reported here: the levels of
mTOR, p70S6K1 and other related proteins decreased in
the W group, suggesting failure in placental delivery of
nutrition. Conversely, other regulatory processes related
may have been responsible for the foetal impairment ob-
served in group A independent of nutrient supply.
The inoculation of ascitic fluid and the effects of
humoural factors mimicked the results of PIF and WF in
tumour-bearing rats [44]. We previously reported that
WF significantly alters protein metabolism and induces
foetal damage [2, 11, 44]. It is reasonable to infer that
the more severe effects of tumour growth, whether dir-
ect or indirect, result from the activation of the proteo-
lytic pathway in placental tissue (increased MuRF-1 and
ubiquitin gene and protein expression), especially in the
W group and, to a lesser extent, in the A group. This
process is responsible for placental failure and conse-
quent foetal damage.
Our study highlights the important role of a leucine-
rich diet in modulating placental cell activity and main-
taining antioxidative response during tumour growth. As
many other studies have proposed, leucine, one of the
three branched-chain amino acids, can act as a cellular
signal to increase protein synthesis downstream of
mTOR, p70S6K1 and eIF4G in skeletal muscle [45–47].
In a previous report, we also demonstrated that con-
sumption of a leucine-rich diet enhances protein syn-
thesis in muscle. Moreover, leucine can improve
cellular responses to antioxidative stress and reduce
proteolysis by inhibiting the ubiquitin-proteasome
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pathway [27, 48–51]. Despite foetal weight loss, the
tumour-bearing group that received leucine nutri-
tional supplementation exhibited improvements in
foetal number and resorption as well as in placental
tissue, the most crucial factor in maintaining a nor-
mal pregnancy course.
As in previous studies in our laboratory, we found that
tumour growth promotes intense mobilisation of muscle
proteins associated with diminished protein synthesis
[25–27]. Tumour-induced placenta damage was related
to changes in key protein-synthesis proteins and in-
creased proteolysis. Similar to other studies, nutritional
leucine supplementation did not prevent all harmful ef-
fects on foetal development, but it did minimise some of
the harmful effects on placental cell activity, enhance
protein synthesis and reduce placental proteolysis caused
by the direct and indirect effects of tumour growth.
However, consistent with increased foetal numbers and
reduced foetal absorption rates, alterations in protein
synthesis and degradation were observed, as reflected by
placental protein balance. This demonstrates that tumour
growth (both directly, as in groups W and WL, and indir-
ectly, as in groups A and LA) promotes important changes
in the maternal-foetal unit, and these changes can be ame-
liorated with nutritional leucine supplementation.
Conclusions
In the current study, we demonstrated that dietary leu-
cine supplementation enhances placental cell signalling,
ameliorates deleterious alterations in DNA and protein
content, and increases placental cell number. Leucine
supplementation also improved the balance between
protein synthesis and degradation in the placenta. This
was reflected in enhanced cell signalling, including sig-
nalling via the mTOR/eIF pathway. Additional experi-
ments are being conducted to better understand the
effects produced by ascitic fluid injection and to deter-
mine the mechanisms by which leucine improves pla-
cental metabolism and counteracts the effects of tumour
growth.
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